Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Sr One
AddedFeb 13, 2024
UpdatedJun 28, 2026
Sr One

Sr One

Operating

SR One, GlaxoSmithKline's venture arm, globally invests in innovative life science companies impacting healthcare.

Location
Conshohocken, PA, US
Founded
1985
Firm
Compare
Portfolio
Employees
Website

Investments

Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series C$101MDecember 2023
Series B$168MOctober 2022
Series A$218MDecember 2021
Avalyn Pharma
Avalyn Pharma

Total Raised

$272.5M

Rounds

3

Series C$175MSeptember 2023
Nimbus Therapeutics
Nimbus Therapeutics
Public

Total Raised

$637M

Rounds

9

Private Equity$210MSeptember 2023
Late Stage Private$125MSeptember 2022
Fore Biotherapeutics
Fore Biotherapeutics

Total Raised

$166.5M

Rounds

9

Series D$75MAugust 2023
Series C$57MSeptember 2020
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Series B$46MJanuary 2023
Series B$75MSeptember 2021
Rezo Therapeutics
Rezo Therapeutics

Total Raised

$78M

Rounds

1

Series A$78MNovember 2022
Ancora Biotech
Ancora Biotech

Total Raised

$60M

Rounds

1

Series A$60MJune 2022
Dren Bio
Dren Bio

Total Raised

$130.1M

Rounds

4

Series B$65MJune 2022
Series A$60MOctober 2020
Simcha Therapeutics
Simcha Therapeutics

Total Raised

$65M

Rounds

2

Series B$40MJanuary 2022
Nomic Bio
Nomic Bio
Series A

Total Raised

$18.2M

Rounds

6

Series A$17MDecember 2021
HotSpot Therapeutics
HotSpot Therapeutics

Total Raised

$210M

Rounds

4

Series C$100MNovember 2021
Series B$65MMay 2020
ARS Pharmaceuticals
ARS Pharmaceuticals
Public

Total Raised

$75M

Rounds

3

Series D$55MAugust 2021
Biotheryx
Biotheryx
Public

Total Raised

$134.7M

Rounds

6

Series E$92MMay 2021
River 2 Renal
River 2 Renal

Total Raised

$40M

Rounds

1

Series A$40MJanuary 2021
River 3 Renal
River 3 Renal

Total Raised

$40M

Rounds

1

Series A$40MJanuary 2021
Palleon Pharmaceuticals
Palleon Pharmaceuticals

Total Raised

$147.6M

Rounds

2

Series B$100MSeptember 2020
Tranquis Therapeutics
Tranquis Therapeutics

Total Raised

$30M

Rounds

1

Series A$30MJuly 2020